US 10/22 E-cigarette seizures: FDA targets big brands in 'deterrent' move, inter-agency enforcement may become the norm

Oct.25.2024
US 10/22 E-cigarette seizures: FDA targets big brands in 'deterrent' move, inter-agency enforcement may become the norm
FDA and CBP jointly seized 3 million unauthorized e-cigarette products worth $76 million, the largest bust in FDA history.The FDA's multi-agency enforcement actions against popular major brands in certain markets require not only short-term measures, such as obtaining Submission Tracking Numbers (STNs), but also long-term planning. Companies are advised to incrementally improve compliance capabilities, establish dedicated compliance departments, and conduct regulatory research to mitigate potent

The US Food and Drug Administration (FDA) and US Customs and Border Protection (CBP) recently conducted a joint operation that resulted in the seizure of approximately 3 million unauthorised e-cigarette products with an estimated retail value of up to $76 million. This is the largest amount ever seized by the FDA. In response to this operation, 2Firsts spoke to several lawyers and compliance professionals who have long monitored the e-cigarette industry.

 

Tang Shunliang, partner at Tianyuan Law Firm and a legal expert in new tobacco areas such as e-cigarettes, and Zheng Zhi, PMTA certification consultant, also discussed their observations and assessments of the event.

 

In the face of a larger scale joint official action and intensified crackdown, they expressed that companies must not only apply for an STN number in the short term as a reaction measure, but also plan for the long term. By gradually improving compliance capabilities and establishing compliance departments for regulatory research, companies can avoid potential legal risks and market losses in the future.

 

 

Industry lawyer warns of 'crackdown as a deterrent' to enforcement in the sector

 

 

Tang Shunliang, a partner at Tianyuan Law Firm and a legal expert on new tobacco products such as e-cigarettes, emphasised that the recent joint enforcement action by the FDA and US Customs sends a strong deterrent signal in addition to its regulatory significance.

 

Tang noted that this enforcement action was not without "warning signs". The FDA has issued numerous warning letters in recent years as part of its Premarket Tobacco Product Application (PMTA) process, signalling a steady increase in regulatory scrutiny of the e-cigarette industry.

 

While the FDA does not have a nationwide enforcement team, it has targeted popular brands in key markets. Tang described this approach as "enforcement as a deterrent", noting that non-compliance by major brands has a broader impact on the market and consumers.

 

"The announcement specifically naming 'GEEKBAR' reflects the FDA's strategy to focus on high-impact brands to regulate the entire industry through such targeted actions," Tang explained.

 

According to Tang, the FDA-Customs joint enforcement was not a random selection, but a calculated move. The compliance of big brands has a lot of influence, which makes them prime targets. Unlike China's nationwide tobacco control network, the FDA's enforcement prioritises large companies as a form of warning.

 

Tang also provided legal context, explaining that the US lacks a comprehensive enforcement network for e-cigarette regulation. Therefore, cooperation between the FDA and Customs is filling this gap. He expects such inter-agency actions to become routine, especially targeting e-cigarette companies that evade duties by misclassifying goods and values.

 

 

PMTA compliance experts: PMTA enters critical phase, companies should respond proactively

 

 

Zheng Zhi, a PMTA compliance consultant with expertise in FDA tobacco regulations, also provided an in-depth analysis of this latest enforcement action.

 

Zheng highlighted that while the FDA began its compliance review of e-cigarette products in 2019, the process has been relatively slow due to the wide range of products involved. Despite the proximity of the 2024 enforcement action to the US presidential election, Zheng noted that these actions are the result of the natural progression of compliance measures rather than purely political motivations.

 

"The FDA's inaction or slow PMTA process has long drawn criticism from multiple fronts. Now, with improved regulations, streamlined procedures and key roles filled, the FDA is ready to accelerate compliance efforts. This action is both a reflection of regulatory pressure and a milestone before the election," commented Zheng.

 

He specifically mentioned that many companies are currently relying on Submission Tracking Numbers (STNs) as a temporary safeguard. However, this approach won't ensure market compliance in the long run. Over time, FDA requirements will increase and companies will need to obtain more advanced compliance certifications, such as Acceptance Letters or File Letters, which will present new challenges.

 

"In my opinion, STNs are only a short-term measure. In the future, more companies will need to meet higher compliance standards, such as obtaining PMTA Acceptance Letters or File Letters. This will raise the bar in terms of resources and skills, making it manageable only for top-tier companies, while smaller companies may struggle to survive or will need to incrementally improve compliance to remain competitive," he explained.

 

 

Future outlook: Enforcement likely to evolve into coordinated inter-agency effort

 

 

Both Tang Shunliang and Zheng Zhi addressed potential enforcement trends regarding misclassification of e-cigarette products and customs evasion.

 

Zheng noted that the recent cooperation between US Customs and the FDA may be just the beginning. As more federal agencies get involved, the regulatory landscape for the e-cigarette industry is expected to become more comprehensive and stringent.

 

"Customs' role may extend beyond simply seizing illegal products; it may increasingly work with the Department of Justice and other federal agencies to create a multi-layered regulatory network. For companies trying to enter the market through illegal means, this could mean no escape," Zheng said.

 

He believes that future US regulation of e-cigarettes will be tightened, with seizures only the first step. Actions involving "grey customs" could even lead to criminal charges. To mitigate such risks, Zheng emphasised the need for companies to accelerate compliance efforts by establishing dedicated compliance teams to ensure their products meet US and international regulatory standards.

 

"For e-cigarette companies with global ambitions - whether brand owners or manufacturers - setting up compliance departments and conducting regulatory research will be essential steps. Compliance is a systematic process, similar to the medical or pharmaceutical industries, and ignoring it could have disastrous consequences," Zheng stressed.

 

Both Tang and Zheng advised that companies need not only short-term solutions but also long-term strategies to gradually improve compliance and avoid potential legal risks and market setbacks.

 

"With US regulatory pressure increasing towards the end of the year, market entry now requires strict adherence to regulatory requirements. Only by raising compliance standards can companies hope to 'survive' in this highly competitive landscape," added Tang.

 

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Latest UK ONS Data: 54% of Vapers Are Former Cigarette Smokers, 26% Also Smoke and 20% Never Smoked Regularly
Latest UK ONS Data: 54% of Vapers Are Former Cigarette Smokers, 26% Also Smoke and 20% Never Smoked Regularly
Former cigarette smokers accounted for an estimated 54% of current e-cigarette users in Great Britain in 2025, while 26% also smoked cigarettes and 20% had never regularly smoked, according to a 2Firsts analysis of Office for National Statistics (ONS) data. Among former cigarette smokers who currently vape, approximately 81% used e-cigarettes daily, compared with about 50% of dual users. The ONS found that 33.8% of current cigarette smokers also vaped in 2025, up from 10.6% in 2014. Approximately 1.1 million adults who had never regularly smoked cigarettes used e-cigarettes, representing 2.9% of that population, compared with 0.2% in 2014. The figures highlight differences in the composition, frequency of use and long-term trends across Britain's vaping population.
DATA
Oct.14
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands reaffirmed its FY26 guidance in its October 8 pre-close trading update, forecasting double-digit net revenue growth in next-generation products and share gains across heated tobacco, vape and modern oral. Tobacco net revenue is expected to grow at a low-single-digit rate, marking a sixth consecutive year of growth. The company has completed its £1.45 billion FY26 share repurchase and announced a £1.5 billion buyback for FY27. Group adjusted operating profit is expected to increase 3% to 5%, while free cash flow is forecast to exceed £2.2 billion.
Oct.09
Malaysia's Poisons Board Backs New Vape Nicotine Exemption After Unanimously Opposing 2023 Proposal
Malaysia's Poisons Board Backs New Vape Nicotine Exemption After Unanimously Opposing 2023 Proposal
Malaysia's Poisons Board has endorsed Health Minister Dzulkefly Ahmad's proposal to exempt liquid nicotine used in vaping products from the Poisons List, according to a November 2, 2026, report by CodeBlue. The Board unanimously opposed a similar proposal in 2023, but the government proceeded with the exemption. The Kuala Lumpur High Court invalidated the 2023 decision in May 2026, and the government withdrew its appeal in August. No new ministerial order has been published. The development raises questions about the interaction between Malaysia's two regulatory frameworks and the treatment of RM354.51 million in excise duties collected on e-cigarette and vape products between May 2023 and June 11, 2026.
Regulations
Nov.03
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
Canada Recalls Nearly 25,000 GTMBAR Vapes Over Child-Resistant Packaging Violations; Brand Linked to Shenzhen GTM Bar, with LK Vape as Importer and Distributor
Canada Recalls Nearly 25,000 GTMBAR Vapes Over Child-Resistant Packaging Violations; Brand Linked to Shenzhen GTM Bar, with LK Vape as Importer and Distributor
Health Canada announced a recall of 24,950 China-made GTMBAR 45K disposable vaping devices on November 13, 2026, citing non-compliance with child-resistant packaging requirements. The devices were sold in Canada between December 2024 and October 2026 and feature a 20mL e-liquid system with a nicotine concentration of 20 mg/mL. No related incidents or injuries had been reported as of November 12. Quebec-based LK Vape is the Canadian importer and distributor, while Shenzhen GTM bar Electronic Technology Co., Ltd. holds the GTMBAR trademark registration in the United Kingdom.
Regulations
Nov.16
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives